[1] Nevens F, Andreone P, Mazzella G, et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med,2016, 375:631-643.
[2] Mayo M, Wigg AJ, Leggett BA, et al. NGM282. For treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind placebo-controlled trial. Hepatol Commun, 2018,2: 1037-1050.
[3] Brandl K, Hartmann P, Jih LJ, et al. Desregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol,2018,69: 396-405.
[4] Barreyro FJ, Holod S, Finocchietto PV, et al. The pan-caspase inhibitor emricasan(IDN-6556) decrdases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int,2015,35: 953-966. |
